Adults 18 to 30, any sex, with Nicotine Dependence. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Drug Effects Questionnaire (DEQ)- 'Good Drug Effects'Primary· up to 55 minutes post-infusion
The Drug Effects Questionnaire (DEQ) is used in studies of acute subjective response (SR) to a variety of substances. The DEQ consists of 11 questions: cooling effect, dislike the sensation, any sensations, feel a drug effect, high, feel stimulated, feel a head rush, like drug effect, dislike any effects, craving a cigarette, and like more of the drug. To calculate the DEQ- 'Good Drug Effects', peak values from post-infusion time points were calculated for the change in the intensity of positive subjective effects as measured with 2 DEQ questions - DEQ question #6 'like drug effect' and DEQ qu
Across Conditions (main effect)
Group
Value
95% CI
Menthol-Preferring Smokers
5.1979
± 0.3803
Non-Menthol Preferring Smokers
6.8384
± 0.4292
High Menthol w High Nicotine
Group
Value
95% CI
Menthol-Preferring Smokers
5.6235
± 0.4731
Non-Menthol Preferring Smokers
7.6285
± 0.5287
High Menthol w Low Nicotine
Group
Value
95% CI
Menthol-Preferring Smokers
5.226
± 0.4766
Non-Menthol Preferring Smokers
7.4351
± 0.5302
High Menthol w Saline
Group
Value
95% CI
Menthol-Preferring Smokers
5.0699
± 0.4768
Non-Menthol Preferring Smokers
7.6285
± 0.5287
Low Menthol w High Nicotine
Group
Value
95% CI
Menthol-Preferring Smokers
5.8971
± 0.4736
Non-Menthol Preferring Smokers
7.5808
± 0.5346
Low Menthol w Low Nicotine
Group
Value
95% CI
Menthol-Preferring Smokers
5.5481
± 0.4809
Non-Menthol Preferring Smokers
6.7656
± 0.5363
Low Menthol w Saline
Group
Value
95% CI
Menthol-Preferring Smokers
4.4655
± 0.4741
Non-Menthol Preferring Smokers
6.3960
± 0.5307
Sponsor's own description
This study will help determine if menthol administered by inhalation via electronic cigarettes (e-cigarette) changes the reinforcing effects of pure nicotine administered intravenously in cigarette smokers who smoke mentholated or non-mentholated cigarettes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
· NA
· recruiting
NCT07250230 — Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Un
· NA
· recruiting
NCT07040566 — A Trial of Varenicline for E-cigarette Cessation
· Phase 2
· recruiting
NCT07001930 — Effects of Cannabidiol on Stress and Nicotine Withdrawal
· Phase 1
· recruiting
NCT06765291 — Behavioral Intervention for Youth to Promote Vaping Cessation
· NA
· recruiting
Other Yale University trials
Trials by the same sponsor.
NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking
· Phase 2
· not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing
· NA
· not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S
· NA
· not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa
· Phase 1, PHASE2
· not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 19 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02102100.